Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.
Clostridium difficile infection (CDI) is the most common cause of identifiable diarrhea in hospitalized patients. The incidence and severity of CDIs are increasing. The increased incidence and severity of the disease has sparked interest in the optimal treatment of CDI as well as the use of new therapies and drug discovery. Current treatment strategies are inadequate with decreased response rates to metronidazole, and high recurrence rates with the use of metronidazole and oral vancomycin. Although incidence rates continue to be low, in vitro resistance to antibiotics used for the treatment of CDI has been noted. Recently, important data has emerged on new anti-C. difficile antibiotics such as rifaximin, rifalazil, fidaxomicin, nitazoxanide, tigecycline and ramoplanin. The purpose of this review is to provide an update on the in vitro susceptibility and new antibiotic treatment options for CDI. This review will focus primarily on scientific studies published in the last 36 months in order to provide an up-to-date review on the topic.
Shah
Dhara
D
University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX 77030, USA.
Dang
Minh-Duc
MD
Hasbun
Rodrigo
R
Koo
Hoonmo L
HL
Jiang
Zhi-Dong
ZD
DuPont
Herbert L
HL
Garey
Kevin W
KW
D000617:Aminoglycosides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D016360:Clostridioides difficile / Q000187:drug effects*; D003015:Clostridium Infections / Q000188:drug therapy* / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D000077732:Fidaxomicin; D006801:Humans; D008826:Microbial Sensitivity Tests; D009574:Nitro Compounds; D016032:Randomized Controlled Trials as Topic; D012294:Rifamycins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000078262:Rifaximin; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D009574:Nitro Compounds; D012294:Rifamycins; D013844:Thiazoles; D000078262:Rifaximin; C041747:nitazoxanide; D000077732:Fidaxomicin
N Engl J Med. 2008 Oct 30;359(18):1932-40
18971494
Antimicrob Agents Chemother. 2004 Nov;48(11):4430-4
15504874
Anaerobe. 2009 Dec;15(6):290-1
19698797
Antimicrob Agents Chemother. 2009 Jan;53(1):223-8
18955525
Antimicrob Agents Chemother. 2002 Jun;46(6):1647-50
12019070
Antimicrob Agents Chemother. 2009 Jan;53(1):261-3
18955523
Antimicrob Agents Chemother. 2004 Oct;48(10):3975-9
15388461
Clin Infect Dis. 2007 Aug 1;45(3):302-7
17599306
South Med J. 2009 Jul;102(7):746-7
19488013
Clin Infect Dis. 2006 Sep 1;43(5):547-52
16886144
Clin Microbiol Infect. 2007 Nov;13(11):1048-57
17850341
J Clin Gastroenterol. 2007 Jan;41(1):38-40
17198063
Antimicrob Agents Chemother. 2003 Jul;47(7):2334-8
12821492
Antimicrob Agents Chemother. 2000 Sep;44(9):2254-8
10952564
Antimicrob Agents Chemother. 1991 Jun;35(6):1108-11
1929250
Antimicrob Agents Chemother. 2008 Aug;52(8):2813-7
18559647
J Antimicrob Chemother. 2008 Nov;62(5):1046-52
18693234
Antimicrob Agents Chemother. 2006 Oct;50(10):3375-80
17005820
Clin Infect Dis. 2007 Mar 15;44(6):846-8
17304459
Anaerobe. 2009 Dec;15(6):234-6
19755166
J Antimicrob Chemother. 2007 Apr;59(4):705-10
17337513
Eur J Clin Microbiol Infect Dis. 1998 Mar;17(3):193-5
9665302
Lancet Infect Dis. 2005 Sep;5(9):549-57
16122678
J Clin Pathol. 2010 Apr;63(4):355-8
20354207
J Clin Gastroenterol. 2009 Jan;43(1):91-3
18385603
Anaerobe. 2004 Aug;10(4):205-11
16701520
Clin Microbiol Infect. 2009 Dec;15(12):1053-66
19929972
Antimicrob Agents Chemother. 2008 Nov;52(11):4163-5
18725442
Antimicrob Agents Chemother. 2005 Mar;49(3):1157-9
15728918
Clin Microbiol Infect. 2009 Dec;15(12):1067-79
19929973
Curr Opin Infect Dis. 2008 Oct;21(5):500-7
18725800
Antimicrob Agents Chemother. 2009 Jan;53(1):281-6
18955526
Clin Infect Dis. 2009 Feb 15;48(4):425-9
19140738
Clin Infect Dis. 2009 Jun 15;48(12):1732-5
19435431
Clin Infect Dis. 2009 Feb 15;48(4):e41-6
19133801
Clin Infect Dis. 2006 Aug 15;43(4):421-7
16838229
Diagn Microbiol Infect Dis. 2006 Feb;54(2):141-4
16406180
Drugs. 2008;68(18):2633-44
19093704
Drugs. 2007;67(13):1947-67
17722965
Int J Antimicrob Agents. 2009 Dec;34(6):516-22
19828299
J Antimicrob Chemother. 2002 Nov;50(5):758-9
12407139
Int J Antimicrob Agents. 2009 Jan;33(1):4-7
18804351
Antimicrob Agents Chemother. 2007 Aug;51(8):2716-9
17517836
J Hosp Infect. 2009 Jun;72(2):111-8
19386381